STOCK TITAN

Exicure, Inc. - XCUR STOCK NEWS

Welcome to our dedicated news page for Exicure (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exicure 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exicure 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
Exicure, Inc.

OTC:XCUR

XCUR Rankings

XCUR Stock Data

4.46M
7.81M
45.04%
9.8%
2.09%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CHICAGO

About XCUR

exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.